Viral hepatitis and HIV in Africa

AIDS Reviews

Volumn 9, Issue 1, 2007, Pages 25-39

  Modi, Apurva A ^a   Feld, Jordan J ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Africa; Coinfection; Hepatitis B; Hepatitis C; HIV

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; DIDANOSINE; EMTRICITABINE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; INTERFERON; ISONIAZID; LAMIVUDINE; NEVIRAPINE; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; RIFAMPICIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; VIRUS DNA; ZIDOVUDINE;

AFRICA; AGE DISTRIBUTION; AIDS RELATED COMPLEX; ANEMIA; BLOOD TRANSFUSION; CANCER RISK; DELTA AGENT HEPATITIS; DENTAL CARE; DISEASE COURSE; DISEASE SEVERITY; DRUG COST; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HEALTH EDUCATION; HEALTH PROGRAM; HEALTH PROMOTION; HEPATITIS A; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS E; HEPATITIS G; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOCOMPROMISED PATIENT; INFECTION PREVENTION; INFECTION RISK; INTRAVENOUS DRUG ABUSE; JAUNDICE; LACTIC ACIDOSIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER TOXICITY; MASS IMMUNIZATION; MASS SCREENING; MITOCHONDRIAL TOXICITY; MORTALITY; NONHUMAN; PROSTITUTION; REVIEW; SEXUAL TRANSMISSION; SIDE EFFECT; SUPERINFECTION; UNSPECIFIED SIDE EFFECT; VERTICAL TRANSMISSION; VIRUS HEPATITIS; VIRUS REPLICATION; VIRUS TRANSMISSION;

AFRICA; COMORBIDITY; GEOGRAPHY; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS;

EID: 34248388580     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (149)

1. UNAIDS. AIDS epidemic update: December 2005. In; 2005; Geneva; 2005.
2. Lok A, McMahon B. Chronic hepatitis B. Hepatology 2001;34:1225-41.
3. CDC Website. Geographic Distribution of Hepatitis B. http://www.cdc.gov/ ncidod/diseases/hepatitis/slideset/hep_b/slide_9.htm. September 10, 2006.
4. WHO Hepatitis B Fact-sheet. http://www.who.int/mediacentre/fact-sheets/ fs204/en/ September 10, 2006.
5. Ahmed S, Cuevas L, Brabin B, et al. Seroprevalence of hepatitis B and C and HIV in Malawian pregnant women. J Infect 1998;37: 248-51.
6. Candotti D, Mundy C, Kadewele G, Nkhoma W, Bates I, Allain J. Serological and molecular screening for viruses in blood donors from Ntcheu, Malawi: high prevalence of HIV-1 subtype C and of markers of hepatitis B and C viruses. J Med Virol 2001;65:1-5.
7. Lodenyo H, Schoub B, Ally R, Kairu S, Segal I. Hepatitis B and C virus infections and liver function in AIDS patients at Chris Hani Baragwanath Hospital, Johannesburg. East Afr Med J 2000;77:13-5.
8. Menendez C, Sanchez-Tapias J, Kahigwa E, et al. Prevalence and mother-to-infant transmission of hepatitis viruses B, C, and E in Southern Tanzania. J Med Virol 1999;58:215-20.
9. Nacro B, Dao B, Dahourou H. HBs antigen in children with suspicion of HIV infection. J Trop Pediatr 2001;47:303-4.
10. Nakwagala F, Kagimu M. Hepatitis B virus and HIV infections among patients in Mulago hospital. East Afr Med J 2002;79:68-72.
11. Ogutu E, Amayo E, Okoth F, Lule G. The prevalence of hepatitis B surface antigen (HBsAg), anti-hepatitis B surface (anti-HBs) and anti-hepatitis B core (anti-HBc) in patients with AIDS. East Afr Med J 1990;67:355-8.
12. Pawlotsky J, Belec L, Gresenguet G, et al. High prevalence of hepatitis B, C, and E markers in young sexually active adults from the Central African Republic. J Med Virol 1995;46:269-72.
13. Shao J, Haukenes G, Yangi E, Vollset S. Association of hepatitis B and HIV infections in Tanzanian population groups. Eur J Clin Microbiol Infect Dis 1993;12:62-4.
14. Ter Meulen J, Wittkowski K, Kidenya J, et al. Evaluation of seroepidemiological associations between HIV-infection, hepatitis B and other sexually transmitted diseases in African patients. Eur J Epidemiol 1989;5:158-63.
15. Combe P, La Ruche G, Bonard D, et al. Hepatitis B and C infections, HIV and other sexually transmitted infections among women of childbearing age in Cote d'Ivoire, West Africa. Trans R Soc Trop Med Hyg 2001;95:493-6.
16. Sutcliffe S, Taha T, Kumwenda N, Taylor E, Liomba G. HIV-1 prevalence and herpes simplex virus 2, hepatitis C virus, and hepatitis B virus infections among male workers at a sugar estate in Malawi. J Acquir Immune Defic Syndr 2002;31:90-7.
17. Burnett R, Francois G, Hoosen A, et al. Three-year analysis of HBV infection in HIV-infected antenatal women from national HIV surveys in South Africa. Proceedings of the 11th International Symposium on Viral Hepatitis and liver disease, Sydney, Australia, April 2003 [abstract WC4-01).
18. Rouet F, Chaix M, Inwoley A, et al. HBV and HCV prevalence and viremia in HIV-positive and HIV-negative pregnant women in Abidjan, Cote d'Ivoire: the ANRS 1236 study. J Med Virol 2004;74:34-40.
19. Oshitani H, Kasolo F, Mpabalwani M, et al. Prevalence of hepatitis B antigens in HIV-1 seropositive and seronegative pregnant women in Zambia. Trans R Soc Trop Med Hyg 1996;90:235-6.
20. Ejele D, Nwauche C, Erhabor O. The prevalence of hepatitis B surface antigenemia in HIV-positive patients in the Niger Delta Nigeria. Niger J Med 2004;13:175-9.
21. Uneke C, Ogbu O, Inyama P, Anyanwu G, Njoku M, Idoko J. Prevalence of hepatitis-B surface antigen among blood donors and HIV-infected patients in Jos, Nigeria. Mem Inst Oswaldo Cruz 2005;100:13-6.
22. Matee M, Magesa P, Lyamuya E. Seroprevalence of HIV, hepatitis B and C viruses and syphilis infections among blood donors at the Muhimbili National Hospital in Dar es Salaam, Tanzania. BMC Public Health 2006;6:21.
23. Matee M, Lyamuya E, Mbena E, et al. Prevalence of transfusion-associated viral infections and syphilis among blood donors in Muhimbili Medical Centre, Dar es Salaam, Tanzania. East Afr Med J 1999;76:167-71.
24. Davis L, Weber D, Lemon S. Horizontal transmission of HBV. Lancet 1989;1:889-93.
25. Vento S, Di Perri G, Garofano T, Concia E, Bassetti D. Reactivation of hepatitis B in AIDS. Lancet 1989;2:108-9.
26. Kew M. Progress towards the comprehensive control of hepatitis B in Africa: a view from South Africa. Gut 1996;38(Suppl 2):S31-6.
27. Kiire C. The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: a view from tropical and subtropical Africa. Gut 1996;38(Suppl 2):S5-12.
28. Mphahlele M, Francois G, Kew M, Van Damme P, Hoosen A, Meheus A. Epidemiology and control of hepatitis B: implications for eastern and southern Africa. S Afr J epidemiol Infect 2002;17:12-7.
29. Nur Y, Groen J, Elmi A, Ott A, Osterhaus A. Prevalence of serum antibodies against bloodborne and sexually transmitted agents in selected groups in Somalia. Epidemiol Infect 2000;124:137-41.
30. Herrero Martinez E. Hepatitis B and hepatitis C coinfection in patients with HIV. Rev Med Virol 2001;11:253-70.
31. Ansa V, Udoma E, Umoh M, Anah M. Occupational risk of infection by HIV and HBV among health workers in southeastern Nigeria. East Afr Med J 2002;79:254-6.
32. Drucker E, Alcabes P, Marx P. The injection century: massive unsterile injections and the emergence of human pathogens. Lancet 2001;358:1989-92.
33. Hauri A, Armstrong D, Hutin Y. The global burden of disease attributable to contaminated injections given in health care settings. Int J STD AIDS 2004;15:7-16.
34. Mayans M, Hall A, Inskip H, et al. Do bedbugs transmit hepatitis B? Lancet 1994;343:761-3.
35. Simonsen L, Kane A, Lloyd J, Zaffran M, Kane M. Unsafe injections in the developing world and transmission of blood-borne pathogens: a review. Bull World Health Organ 1999;77:789-800.
36. Vall Mayans M, Hall A, Inskip H, et al. Risk factors for transmission of HBV to Gambian children. Lancet 1990;336:1107-9.
37. Chikwem,J, Mohammed I, Okara G, Ukwandu N, Ola T. Prevalence of transmissible blood infections among blood donors at the University of Maiducuri Teaching Hospital, Maiduguri, Nigeria. East Afr Med J 1997;74:213-6.
38. Allain J, Candotti D, Soldan K, et al. The risk of HBV infection by transfusion in Kumasi, Ghana. Blood 2003;101:2419-25.
39. Hadler S, Judson F, O'Malley P, et al. Outcome of HBV infection in homosexual men and its relation to prior HIV infection. J Infect Dis 1991;163:454-9.
40. Bodsworth N, Donovan B, Nightingale B. The effect of concurrent HIV infection on chronic hepatitis B: a study of 150 homosexual men. J Infect Dis 1989;160:577-82.
41. Colin J, Cazals-Hatem D, Loriot M, et al. Influence of HIV infection on chronic hepatitis B in homosexual men. Hepatology 1999;29:1306-10.
42. Gilson R, Hawkins A, Beecham M, et al. Interactions between HIV and HBV in homosexual men: effects on the natural history of infection. Aids 1997;11:597-606.
43. Konopnicki D, Mocroft A, de Wit S, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to HAART and increased mortality in the EuroSIDA cohort. Aids 2005;19:593-601.
44. Puoti M, Spinetti A, Ghezzi A, et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr 2000;24:211-7.
45. Thio C, Seaberg E, Skolasky R, et al. HIV-1, HBV, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002;360:1921-6.
46. Otedo A. HBV, HIV coinfection at Kisumu District Hospital, Kenya. East Afr Med J 2004;81:626-30.
47. Di Martino V, Thevenot T, Colin J, et al. Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B. Gastroenterology 2002;123:1812-22.
48. Scharschmidt B, Held M, Hollander H, et al. Hepatitis B in patients with HIV infection: relationship to AIDS and patient survival. Ann Intern Med 1992;117:837-8.
49. Sinicco A, Raiteri R, Sciandra M, et al. Coinfection and superinfection of HBV in patients infected with HIV: no evidence of faster progression to AIDS. Scand J Infect Dis 1997;29:111-5.
50. Chamorro A, Casado J, Bellido D, Moreno S. Reactivation of hepatitis B in an HIV-infected patient with antibodies against hepatitis B core antigen as the only serological marker. Eur J Clin Microbiol Infect Dis 2005;24:492-4.
51. DeSimone J, Pomerantz R, Babinchak T. Inflammatory reactions in HIV-1-infected persons after initiation of HAART. Ann Intern Med 2000;133:447-54.
52. Shelburne S, Hamill R, Rodriguez-Barradas M, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during HAART, Medicine (Baltimore) 2002;81:213-27.
53. French M, Lenzo N, John M, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with HAART. HIV Med 2000;1:107-15.
54. Michelet C, Arvieux C, Francois C, et al. Opportunistic infections occurring during HAART. Aids 1998;12:1815-22.
55. Carr A, Cooper D. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor. Lancet 1997;349:995-6.
56. Drake A, Mijch A, Sasadeusz J. Immune reconstitution hepatitis in HIV and HBV coinfection, despite lamivudine therapy as part of HAART. Clin Infect Dis 2004;39:129-32.
57. Sulkowski M, Thomas D, Mehta S, Chaisson R, Moore R. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002;35:182-9.
58. Velasco M, Moran A, Tellez M. Resolution of chronic hepatitis B after ritonavir treatment in an HIV-infected patient. N Engl J Med 1999;340:1765-6.
59. Nunez M, Lana R, Mendoza J, Martin-Carbonero L, Soniano V. Risk factors for severe hepatic injury after introduction of HAART. J Acquir Immune Defic Syndr 2001;27:426-31.
60. Abrescia N, D'Abbraccio M, Figoni M, et al. Fulminant hepatic failure after the start of an elavirenz-based HAART regimen in a treatment-naive female AIDS patient without hepatitis virus coinfection. J Antimicrob Chemother 2002;50:763-5.
61. Kramvis A, Restorp K, Norder H, Botha J, Magnius L, Kew M. Full genome analysis of HBV genotype E strains from Southwestern Africa and Madagascar reveals low genetic variability. J Med Virol 2005;77:47-52.
62. Tanaka Y, Hasegawa I, Kato T, et al. A case-control study for differences among HBV infections of genotypes A (subtypes Aa and Ae) and D. Hepatology 2004;40:747-55.
63. Benhamou Y, Bochet M, Thibault V, et al. Safety and efficacy of adefovir dipivoxil in patients coinfected with HIV-1 and lamivudine-resistant HBV: an open-label pilot study. Lancet 2001;358:718-23.
64. Benhamou Y, Katlama C, Lunel F, et al. Effects of lamivudine on replication of HBV in HIV-infected men. Ann Intern Med 1996;125:705-12.
65. Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1. J Hepatol 2006;44:62-7.
66. Benhamou Y, Tubiana V, Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant HBV. N Engl J Med 2003;348:177-8.
67. Dore G, Cooper D, Barrett C, Goh L, Thakrar B, Atkins M. Dual efficacy of lamivudine treatment in HIV/HBV-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee. J Infect Dis 1999;180:607-13.
68. Dore G, Cooper D, Pozniak A, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and -experienced patients coinfected with HIV-1 and HBV. J Infect Dis 2004;189:1185-92.
69. Hoff J, Bani-Sadr F, Gassin M, Raffi F. Evaluation of chronic HBV infection in coinfected patients receiving lamivudine as a component of anti-HIV regimens. Clin Infect Dis 2001;32:963-9.
70. Nelson M, Portsmouth S, Stebbing J, et al. An open-label study of tenofovir in HIV-1 and HBV coinfected individuals. Aids 2003;17: F7-10.
71. Nunez M, Perez-Olmeda M, Diaz B, Rios P, Gonzalez-Lahoz J, Soriano V. Activity of tenofovir on HBV replication in HIV-coinfected patients failing or partially responding to lamivudine. Aids 2002;16:2352-4.
72. Snow A, Harris J, Borroto-Esoda K, et al. Emtricitabine therapy for hepatitis infection in HIV+ patients cointected with HBV: efficacy and genotypic findings in antiretroviral treatment-naive patients. Presented at the 11th CROI, Boston, MA.
73. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of HBV resistance to lamivudine in HIV-infected patients. Hepatology 1999;30:1302-6.
74. Bessesen M, Ives D, Condreay L, Lawrence S, Sherman K. Chronic active hepatitis B exacerbations in HIV-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999;28:1032-5.
75. Lim S, Wai C, Rajnakova A, Kajiji T, Guan R. Fatal hepatitis B reactivation following discontinuation of nucleoside analogs for chronic hepatitis B. Gut 2002;51:597-9.
76. Wong D, Yim C, Naylor C, et al. Interferon-α treatment of chronic hepatitis B: randomized trial in a predominantly homosexual male population. Gastroenterology 1995;108:165-71.
77. Hofer M, Joller-Jemelka H, Grob P, Luthy R, Opravil M. Frequent chronic HBV infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV Cohort Study. Eur J Clin Microbiol Infect Dis 1998;17:6-13.
78. Laure F, Zagury D, Saimot A, Gallo R, Hahn B, Brechot C. HBV-DNA sequences in lymphoid cells from patients with AIDS and AIDS-related complex. Science 1985;229:561-3.
79. Piroth L, Binquet C, Vergne M, et al. The evolution of HBV serological patterns and the clinical relevance of isolated antibodies to hepatitis B core antigen in HIV-infected patients. J Hepatol 2002;36:681-6.
80. Grob P, Jilg W, Bornhak H, et al. Serological pattern "anti-HBc alone": report on a workshop. J Med Virol 2000;62:450-5.
81. Mphahlele M, Lukhwareni A, Burnett H, Moropeng L, Ngobeni J. High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa. J Clin Virol 2006;35:14-20.
82. Poovorawan Y, Sanpavat S, Pongpunlert W, Chumdermpadetsuk S, Sentrakul P, Safary A. Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. Jama 1989;261:3278-81.
83. Van Zonneveld M, van Nunen A, Niesters H, de Man R, Schalm S, Janssen H. Lamivudine treatment during pregnancy to prevent perinatal transmission of HBV infection. J Viral Hepat 2003; 10:294-7.
84. Yang H, Lu S, Liaw Y, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168-74.
85. Turner P, Sylla A, Diallo M, Castegnaro J, Hall A, Wild C. The role of aflatoxin and hepatitis viruses in the etiopathogenesis of hepatocellular carcinoma: A basis for primary prevention in Guinea-Conakry, West Africa. J Gastroenterol Hepatol 2002;17(Suppl):S441-8.
86. Kew M, Kramvis A, Yu M, Arakawa K, Hodkinson J. Increased hepatocarcinogenic potential of hbv genotype A in Bantu-speaking sub-Saharan Africans. J Med Virol 2005;75:513-21.
87. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999;6:35-47.
88. Boyer N, Marcellin P. Pathogenesis, diagnosis and management of hepatitis C. J Hepatol 2000;32(Suppl 1):98-112.
89. Furrer H, Fux C. Opportunistic infections: an update. J HIV Ther 2002;7:2-7.
90. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with HIV infection. Clin Infect Dis 2001;32:492-7.
91. Soriano V, Garcia-Samaniego J, Valencia E, Rodriguez-Rosado R, Munoz F, Gonzalez-Lahoz J. Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol 1999;15:1-4.
92. Madhava V, Burgess C, Drucker E. Epidemiology of chronic HCV infection in sub-Saharan Africa. Lancet Infect Dis 2002;2:293-302.
93. el-Sayed N, Gomatos P, Rodier G, et al. Seroprevalence survey of Egyptian tourism workers for HBV, HCV, HIV, and Treponema pallidum infections: association of HCV infections with specific regions of Egypt. Am J Trop Med Hyg 1996;55:179-84.
94. Njouom R, Pasquier C, Ayouba A, et al. Low risk of mother-to-child transmission of HCV in Yaounde, Cameroon: ANRS 1262 study. Am J Trop Med Hyg 2005;73:460-6.
95. Kallestrup P, Zinyama R, Gomo E, et al. Low prevalence of HCV antibodies in HIV-endemic area of Zimbabwe support sexual transmission as the major route of HIV transmission in Africa. Aids 2003;17:1400-2.
96. Gisselquist D, Perrin L, Minkin S. Parallel and overlapping HIV and bloodborne hepatitis epidemics in Africa. Int J STD AIDS 2004; 15:145-52.
97. Memon M, Memon M. Hepatitis C: an epidemiologic review. J Viral Hepat 2002;9:84-100.
98. Simpore J, Ilboudo D, Samandoulougou A, Guardo P, Castronovo P, Musumeci S. HCV and HIV coinfection in pregnant women attending St. Camille Medical Centre in Ouagadougou (Burkina Faso). J Med Virol 2005;75:209-12.
99. Kitundu J, Msengi A, Matee M, et al. Posttransfusion hepatitis C seroprevalence in Tanzanian children. Ann Trop Paediatr 2001; 21:343-8.
100. Sherman K, Rouster S, Chung R, Rajicic N. HCV prevalence among patients infected with HIV: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002;34:831-7.
101. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in HIV and HCV coinfected patients. The Multivirc Group. Hepatology 1999;30:1054-8.
102. Puoti M, Bonacini M, Spinetti A, et al. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with HCV and HIV. J Infect Dis 2001;183:134-7.
103. Graham C, Baden L, Yu E, et al. Influence of HIV infection on the course of HCV infection: a meta-analysis. Clin Infect Dis 2001;33:562-9.
104. El-Serag H, Giordano T, Kramer J, Richardson P, Souchek J. Survival in HCV and HIV coinfection: a cohort study of hospitalized veterans. Clin Gastroenterol Hepatol 2005;3:175-83.
105. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and HCV coinfection: the Swiss HIV Cohort Study. Lancet 2000;356:1800-5.
106. Sulkowski M, Moore R, Mehta S, Chaisson R, Thomas D. Hepatitis C and progression of HIV disease. Jama 2002;288:199-206.
107. Yoo T, Donfield S, Lail A, Lynn H, Daar E. Effect of HCV genotype on HCV and HIV-1 disease. J Infect Dis 2005;191:4-10.
108. Pasquier C, Njouom R, Ayouba A, et al. Distribution and heterogeneity of hepatitis C genotypes in hepatitis patients in Cameroon. J Med Virol 2005;77:390-8.
109. Chung R, Andersen J, Volberding P, et al. PEG-IFNα-2a plus ribavirin versus IFNα-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004;351:451-9.
110. Torriani F, Rodriguez-Torres M, Rockstroh J, et al. PEG-IFNα-2a plus ribavirin for chronic HCV infection in HIV-infected patients. N Engl J Med 2004;351:438-50.
111. Balzarini J, Lee C, Herdewijn F, De Clercq E. Mechanism of the potentiating effect of ribavirin on the activity of 2′,3′-dideoxyinosine against HIV. J Biol Chem 1991; 266:21509-14.
112. Fuster D, Huertas J, Gomez G, et al. Short communication. Baseline factors associated with hematologic toxicity that leads to a dosage reduction of PEG-IFNα-2a and ribavirin in HIV/HCV-coinfected patients on HCV antiviral therapy. Antivir Ther 2005;10:841-7.
113. Chang M. Impact of hepatitis B vaccination on hepatitis B disease and nucleic acid testing in high-prevalence populations. J Clin Virol 2006;36(Suppl 1):S45-50.
114. Caredda A, d'Arminio Monforte A, Rossi E, et al. Prospective study of epidemic delta infection in drug addicts. Prog Clin Biol Res 1983;143:245.
115. Pol S, Wesenfelder L, Dubois F, et al. Influence of HIV infection on hepatitis delta virus superinfection in chronic HBsAg carriers. J Viral Hepat 1994;1:131-7.
116. Jenhani F, Ayed K, Gorgi Y, Zoulim F, Pichoud C, Trepo C. Delta infection in chronic HBsAg carriers in Tunisia: high prevalence in chronic asymptomatic HBsAg carriers and in HBsAg positive cirrhosis. Ann Trop Med Parasitol 1990;84:349-53.
117. Ndumbe P. Hepatitis D in Yaounde, Cameroon. Apmis 1991;99:196-8.
118. Roingeard P, Sankale J, Dubois F, et al. Infection due to hepatitis delta virus in Africa: report from Senegal and review. Clin Infect Dis 1992;14:510-4.
119. Triki H, Said N, Ben Salah A, et al. Seroepidemiology of hepatitis B, C and delta viruses in Tunisia. Trans R Soc Trop Med Hyg 1997;91:11-4.
120. De Lalla F, Rizzardini G, Rinaldi E, Santoro D, Zeli P, Verga G. HIV, HBV, delta-agent and Treponema pallidum infections in two rural African areas. Trans R Soc Trop Med Hyg 1990;84:144-7.
121. Ojo D, Akonai A, Thursz M, et al. HDV antigen in HBsAg positive chronic liver disease in Nigeria. East Afr Med J 1998;75:329-31.
122. Ojo D, Thursz M, Thomas H, et al. HBV markers, HDV antigen and HCV antibodies in Nigerian patients with chronic liver disease. East Afr Med J 1995;72:719-21.
123. Soubeyrand J, Niamkey E, Ouattara S, Diallo D, Leleu J, Beda B. HIV-1 seropositivity and B and D viruses in West Africa. Pathol Biol (Paris) 1990;38:899-902.
124. Puoti M, Rossi S, Forleo M, et al. Treatment of chronic hepatitis D with IFNα-2b in patients with HIV infection. J Hepatol 1998;29:45-52.
125. Wolters L, van Nunen A, Honkoop P, et al. Lamivudine-high dose interferon combination therapy for chronic hepatitis B patients co-infected with the hepatitis D virus. J Viral Hepat 2000;7:428-34.
126. Halasz R, Barkholt L, Lara C, et al. Relation between GB virus C/ hepatitis G virus and fulminant hepatic failure may be secondary to treatment with contaminated blood and/or blood products. Gut 1999;44:274-8.
127. Jarvis L, Davidson F, Hanley J, Yap P, Ludlam C, Simmonds P. Infection with hepatitis G virus among recipients of plasma products. Lancet 1996;348:1352-5.
128. Anastassopoulou C, Paraskevis D, Sypsa V, et al. Prevalence patterns and genotypes of GB virus C/hepatitis G virus among imprisoned intravenous drug users. J Med Virol 1998;56:246-52.
129. de Martino M, Azzari C, Resti M, et al. Hepatitis G virus infection in HIV-1-infected mothers and their children. J Infect Dis 1998;178:862-5.
130. Wejstal R, Manson A, Widell A, Norkrans G. Perinatal transmission of hepatitis G virus (GB virus type C) and HCV infections - a comparison. Clin Infect Dis 1999;28:816-21.
131. Sarrazin D, Roth W, Zeuzem S. Heterosexual transmission of GB virus-C/ hepatitis G virus infection. Eur J Gastroenterol Hepatol 1997;9:1117-20.
132. Scallan M, Clutterbuck D, Jarvis L, Scott G, Simmonds P. Sexual transmission of GB virus C/hepatitis G virus. J Med Virol 1998;55: 203-8.
133. El-Zayadi A, Abe K, Selim O, Naito H, Hess G, Ahdy A. Prevalence of GBV-C/hepatitis G virus viremia among blood donors, health care personnel, chronic non-B non-C hepatitis, chronic hepatitis C and hemodialysis patients in Egypt. J Virol Methods 1999;80:53-8.
134. Cacoub P, Ohayon V, Sekkat S, et al. Epidemiologic and virologic study of HCV infections in Morocco. Gastroenterol Clin Biol 2000; 24:169-73.
135. Liu H, Muyembe-Tamfum J, Dahan K, Desmyter J, Goubau P. High prevalence of GB virus C/hepatitis G virus in Kinshasa, Democratic Republic of Congo: a phylogenetic analysis. J Med Virol 2000;60:159-65.
136. Alter H, Nakatsuji Y, Melpolder J, et al. The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease. N Engl J Med 1997;336:747-54.
137. Chen M, Fischler B, Hultgren C, Halasz H, Nemeth A, Sallberg M. Analysis of GB virus C markers in families over three generations. J Clin Microbiol 1999;37:4153-5.
138. Di S, Ferraro D, Bonura C, et al. Are hepatitis G virus and TT virus involved in cryptogenic chronic liver disease? Dig Liver Dis 2002;34:53-8.
139. Linnen J, Wages J, Zhang-Keck Z, et al. Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science 1996;271:505-8.
140. Tameda Y, Kosaka Y, Tagawa S, et al. Infection with GB virus C (GBV-C) in patients with fulminant hepatitis. J Hepatol 1996;25:842-7.
141. Yoshiba M, Okamoto H, Mishiro S. Detection of the GBV-C hepatitis virus genome in serum from patients with fulminant hepatitis of unknown etiology. Lancet 1995;346:1131-2.
142. Lefrere J, Roudot-Thoraval F, Morand-Joubert L, et al. Carriage of GB virus C/hepatitis G virus RNA is associated with a slower immunologic, virologic, and clinical progression of HIV disease in coinfected persons. J Infect Dis 1999;179:783-9.
143. Tillmann H, Heiken H, Knapik-Botor A, et al. Infection with GB virus C and reduced mortality among HIV-infected patients. N Engl J Med 2001;345:715-24.
144. Yeo A, Matsumoto A, Hisada M, Shih J, Alter H, Goedert J. Effect of hepatitis G virus infection on progression of HIV infection in patients with hemophilia. Multicenter Hemophilia Cohort Study. Ann Intern Med 2000;132:959-63.
145. Karuru J, Lule G, Joshi M, Anzala O. Prevalence of HCV and HCV/HIV coinfection among in-patients at the Kenyatta National Hospital. East Afr Med J 2005;82:170-2.
146. Karuru J, Lule G, Joshi M, Anzala O. Prevalence of HCV and HIV/HCV coinfection among volunteer blood donors and VCT clients. East Afr Med J 2005;82:166-9.
147. Amin J, Kaye M, Skidmore S, Pillay D, Cooper D, Dore G. HIV and hepatitis C coinfection within the CAESAR study. HIV Med 2004;5:174-9.
148. Agwale S, Tanimoto L, Womack C, et al. Prevalence of HCV coinfection in HIV-infected individuals in Nigeria and characterization of HCV genotypes. J Clin Virol 2004;31(Suppl 1):S3-6.
149. Feld J, Ocama P, Ronald A. The liver in HIV in Africa. Antivir Ther 2005;10:953-65.